Pharmaceutical giant Eli Lilly is bringing a $700M research facility to the Boston Seaport, a move that signals a strategy shift and a nine-figure vote of confidence on the future direction of biotech. The Eli Lilly Institute for Genetic Medicine, which is expected to open in 2024, will be a 334K SF new RNA-focused facility in a 12-story building developed and operated by Alexandria Real Estate Equities. The project signifies the importance of a new generation of therapies for the industry, and the competition for talent and startups that will likely consume large pharmaceutical companies.
Along with mRNA pioneer Moderna’s under-construction new Cambridge HQ — also an Alexandria project — Lilly's move highlights the appetite the industry has to bet big on new techniques and technology, and to do it in the heart of Boston.“It’s a defining moment when a major pharma company declares this is going to be… Read the full story here. |